Afrezza...what went wrong???

Discussion in 'MannKind' started by anonymous, Sep 10, 2015 at 4:08 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This drug is great and yet NO scripts...what the hell happened. I lost a ton of $$$$$$.
     

  2. anonymous

    anonymous Guest

    You poor baby... Did you panic and sell? hahahahahahaha
     
  3. anonymous

    anonymous Guest

    I sold 40%.....tell me why you think it will go up...instead of ha.ha
     
  4. anonymous

    anonymous Guest

    What went wrong? This is easy - there is no physician demand for this project. No one wants human insulin in an analog market, regardless of how it may be dosed. Add in, you'll never be able to shake the damage done by Exubera. Bad market conditions. Great technology, but it just won't work in the short-acting insulin market.
     
  5. anonymous

    anonymous Guest

    Betamax was better than VHS, but VHS won in the long run. MS Windows over anything else?
    NTSC television over PALS? Took 50 years to fix that one with digital TV. Best just doesnt always win.
     
  6. anonymous

    anonymous Guest

    The DTC campaign hasn't yet begun. Once the patients learn about this, the docs will have no choice except to write for it.
     
  7. anonymous

    anonymous Guest

    sanofi--king of failed launches.
     
  8. anonymous

    anonymous Guest

    Reason for failure - get reps that can actually sell
     
  9. anonymous

    anonymous Guest

    Fink--Queen of failure!
     
  10. anonymous

    anonymous Guest

    Yeah, because patient demand ALWAYS drives the market for diabetes drugs. :rolleyes:
    We have too many here that remember the onslaught created by patient demand for Claritin and Viagra in the mid 90s, and think that it translates well to blood pressure, high cholesterol and diabetes.

    FALSE!
     
  11. anonymous

    anonymous Guest

    once mannkind starts marketing, it will go bankrupt. no matter how you slice it sanofi was spending $160m/yr on afrezza. mannkind has $60m in the bank and it costs $60m a year just to keep the lights on there (and line the pockets of management). where are they going to find any money to hire a salesforce of any kind?
     
  12. anonymous

    anonymous Guest

    ^^^^ This

    A lot of MNKD longs are upset that Sanofi did not do better with this drug, but despite the conventional wisdom there was a poorly received launch. Were some of the decisions flawed, perhaps so, but MNKD does not have the money to try again with a different approach.

    The thermometer just reached 165 degrees indicating that this goose is fully cooked.
     
  13. anonymous

    anonymous Guest

    I heard it was being moved to a cso company
     
  14. anonymous

    anonymous Guest

  15. anonymous

    anonymous Guest

    Piece of shit drug
     
  16. anonymous

    anonymous Guest

    No one can sell this drug. It's not wanted or needed by 99.9% of patients who take insulin. Docs don't want it either. It was dead before it started.

    On a positive note, MNKD closed at $0.91 a share today.
     
  17. anonymous

    anonymous Guest

    You're a f****n uneducated piece of crap... Check your facts before saying something like that...
     
  18. anonymous

    anonymous Guest

    Quit being so hostile, especially about a drug that doctors don't want. I'm sure you think it's super-awesome. Plenty of people (especially docs) are extremely well-educated on this drug, and they don't want it. Sorry. When 99% of people are on 1 side, and you're on the other telling them how wrong they are, perhaps you should reevaluate your position. Just sayin'....
     
  19. anonymous

    anonymous Guest

    That's why there were 20,000 scripts written and over 14,000 patients trying it. It failed bc Sanofi didn't communicate how to titrate or train on the drug so people didn't maintain control during conversion... Thank god they gave it back to Mannkind, at least they understand the drug. I guess all the patient stories don't support you so you make up stuff
     
  20. anonymous

    anonymous Guest

    FDA labeling and insurance that's your answer.